Shenzhen Ridge Engineering Consulting Co., Ltd. (SHE:300977)

SpringWorks Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	467.73	468.94	490.42	571.45	778.21	572.67
Other Revenue	0.9	0.9	0.89	0.37	-	-
Revenue	468.63	469.84	491.31	571.83	778.21	572.67
Revenue Growth (YoY)	-2.08%	-4.37%	-14.08%	-26.52%	35.89%	15.35%
Cost of Revenue	296.49	298.07	296.12	359.65	460.36	317.79
Gross Profit	172.14	171.77	195.19	212.17	317.85	254.88
Selling, General & Admin	120.49	120.28	114.67	144.47	126.42	79.38
Research & Development	33.96	33.51	29.09	30.54	34.38	30.29
Other Operating Expenses	2.89	2.65	2.91	0.78	1.43	1.78
Operating Expenses	206.69	210.5	178.63	225.57	205.82	118.27
Operating Income	-34.55	-38.73	16.57	-13.39	112.03	136.61
Interest Expense	-0.59	-0.49	-0.59	-2.69	-0.57	-
Interest & Investment Income	16.96	23.62	31.79	28.32	13.84	2.87
Currency Exchange Gain (Loss)	-0.26	-0.26	-	-	-	-
Other Non Operating Income (Expenses)	-0.6	-0.69	-0.42	0.23	-0.16	-0.31
EBT Excluding Unusual Items	-19.04	-16.56	47.34	12.47	125.14	139.18
Gain (Loss) on Sale of Investments	4.14	0.39	-10.87	3.47	3.97	-
Gain (Loss) on Sale of Assets	-0.16	-0.06	-0.68	-0.06	0.13	-
Asset Writedown	-18.45	-18.62	-2.6	-1.88	-0.02	-
Other Unusual Items	0.65	0.31	10.29	3.59	8.61	1.79
Pretax Income	-32.86	-34.54	43.48	17.6	137.83	140.97
Income Tax Expense	-10.31	-10.87	1.21	1.82	18.69	20.54
Earnings From Continuing Operations	-22.55	-23.67	42.26	15.78	119.14	120.43
Minority Interest in Earnings	-2.01	-2	-1.4	-0.1	-	-
Net Income	-24.56	-25.67	40.87	15.68	119.14	120.43
Net Income to Common	-24.56	-25.67	40.87	15.68	119.14	120.43
Net Income Growth	-	-	160.65%	-86.84%	-1.07%	-13.28%
Shares Outstanding (Basic)	147	151	151	157	143	113
Shares Outstanding (Diluted)	147	151	151	157	144	113
Shares Change (YoY)	-5.87%	-0.25%	-3.46%	8.79%	27.11%	-0.09%
EPS (Basic)	-0.17	-0.17	0.27	0.10	0.83	1.06
EPS (Diluted)	-0.17	-0.17	0.27	0.10	0.83	1.06
EPS Growth	-	-	170.00%	-87.90%	-22.17%	-13.20%
Free Cash Flow	-9.31	-1.04	62.75	-61.14	50.46	66.39
Free Cash Flow Per Share	-0.06	-0.01	0.41	-0.39	0.35	0.59
Dividend Per Share	-	-	0.220	0.033	0.311	0.264
Dividend Growth	-	-	560.66%	-89.30%	17.71%	-
Gross Margin	36.73%	36.56%	39.73%	37.10%	40.84%	44.51%
Operating Margin	-7.37%	-8.24%	3.37%	-2.34%	14.40%	23.86%
Profit Margin	-5.24%	-5.46%	8.32%	2.74%	15.31%	21.03%
Free Cash Flow Margin	-1.99%	-0.22%	12.77%	-10.69%	6.48%	11.59%
EBITDA	-32.24	-35.52	23.36	-7.81	113.73	137.73
EBITDA Margin	-6.88%	-7.56%	4.75%	-1.37%	14.61%	24.05%
D&A For EBITDA	2.32	3.21	6.8	5.58	1.69	1.12
EBIT	-34.55	-38.73	16.57	-13.39	112.03	136.61
EBIT Margin	-7.37%	-8.24%	3.37%	-2.34%	14.40%	23.86%
Effective Tax Rate	-	-	2.79%	10.35%	13.56%	14.57%
Revenue as Reported	468.63	469.84	491.31	571.83	778.21	572.67

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.